Atara Biotherapeutics Inc. (NASDAQ: ATRA) stock jumped 1.96% on Monday to $1.56 against a previous-day closing price of $1.53. With 1.42 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.42 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.5772 whereas the lowest price it dropped to was $1.4700. The 52-week range on ATRA shows that it touched its highest point at $5.64 and its lowest point at $1.25 during that stretch. It currently has a 1-year price target of $14.72. Beta for the stock currently stands at 1.01.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATRA was down-trending over the past week, with a drop of -7.14%, but this was down by -2.50% over a month. Three-month performance dropped to -22.39% while six-month performance fell -48.34%. The stock lost -66.81% in the past year, while it has lost -52.44% so far this year. A look at the trailing 12-month EPS for ATRA yields -2.94 with Next year EPS estimates of -1.88. For the next quarter, that number is -0.65. This implies an EPS growth rate of 38.40% for this year and 28.00% for next year.
Float and Shares Shorts:
At present, 105.09 million ATRA shares are outstanding with a float of 98.66 million shares on hand for trading. On Aug 30, 2023, short shares totaled 11.53 million, which was 11.40% higher than short shares on Jul 30, 2023. In addition to Dr. Pascal Touchon D.V.M. as the firm’s Pres, CEO & Director, Mr. K. Amar Murugan serves as its Exec. VP & Chief Legal Officer.
Through their ownership of 107.64% of ATRA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 55.72% of ATRA, in contrast to 35.20% held by mutual funds. Shares owned by individuals account for 12.56%. As the largest shareholder in ATRA with 9.67% of the stake, The Baupost Group LLC holds 9,773,616 shares worth 9,773,616. A second-largest stockholder of ATRA, Wasatch Advisors, Inc., holds 8,283,981 shares, controlling over 8.19% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in ATRA, holding 7,186,796 shares or 7.11% stake. With a 2.68% stake in ATRA, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,710,236 shares are owned by the mutual fund manager. The JPMorgan Small Cap Growth Fund, which owns about 2.40% of ATRA stock, is the second-largest Mutual Fund holder. It holds 2,425,329 shares valued at 3.54 million. Wasatch Small Cap Growth Fund holds 2.35% of the stake in ATRA, owning 2,371,687 shares worth 3.46 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, ATRA reported revenue of $51.58M and operating income of -$32.13M. The EBITDA in the recently reported quarter was -$80.93M and diluted EPS was $0.18.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATRA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATRA analysts setting a high price target of $31.00 and a low target of $1.40, the average target price over the next 12 months is $16.19. Based on these targets, ATRA could surge 1887.18% to reach the target high and fall by -10.26% to reach the target low. Reaching the average price target will result in a growth of 937.82% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded ATRA stock several times over the past three months with 0 Buys and 13 Sells. In these transactions, 0 shares were bought while 87,362 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 30 over the past year. The total number of shares bought during that period was 1,160,114 while 216,605 shares were sold.